BioLineRx Ltd. , a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, announced today that in light of encouraging pharmacodynamic and excellent safety data from the ongoing Phase 2 clinical trial of BL-8040 for the treatment of patients with relapsed or refractory acute myeloid leukemia , the Company has filed with the U.S. Food and Drug Administration an amendment to the study protocol to test additional cohorts at higher doses in the current dose-escalation stage of the trial. The amendment will also include an increase in the total expected study enrollment, from up to 50 under the original protocol, to up to 70 patients.
http://ift.tt/1zrHsfg
http://ift.tt/1zrHsfg
No comments:
Post a Comment